Patients’ demographic and clinical characteristics by stage and type of therapy for advanced NSCLC who were diagnosed and treated between 2014–2019 in the Netherlands
| Characteristics | Total cohort advanced NSCLC (n=10 306) | ||||
| Total, N* | Stage III ChemoRT (n=2772) Patients, % | Stage III RT (n=1359) Patients, % | Stage III ST (n=907) Patients, % | Stage IV ST (n=5268) Patients, % | |
| Age (years) | |||||
| 18–60 | 2655 | 792 (29) | 220 (16) | 189 (21) | 1454 (28) |
| 61–70 | 3928 | 1125 (40) | 391 (29) | 353 (39) | 2059 (39) |
| 71–80 | 3062 | 754 (27) | 482 (35) | 294 (32) | 1532 (29) |
| 80+ | 661 | 101 (4) | 266 (20) | 71 (8) | 223 (4) |
| Gender | |||||
| Male | 5878 | 1600 (58) | 861 (63) | 513 (57) | 2904 (55) |
| Female | 4428 | 1172 (42) | 498 (37) | 394 (43) | 2364 (45) |
| Socioeconomic status | |||||
| Low | 5864 | 1615 (58) | 756 (56) | 524 (58) | 2969 (56) |
| Intermediate | 2422 | 658 (24) | 315 (23) | 228 (25) | 1221 (23) |
| High | 2020 | 499 (18) | 288 (21) | 155 (17) | 1078 (21) |
| History of other cancer | |||||
| Yes | 748 | 207 (7) | 146 (11) | 86 (9) | 309 (6) |
| No | 9558 | 2565 (93) | 1213 (89) | 821 (91) | 4959 (94) |
| Year of diagnosis | |||||
| 2014 | 1349 | 432 (16) | 177 (13) | 128 (14) | 612 (12) |
| 2015–2016 | 3410 | 935 (34) | 486 (36) | 297 (33) | 1692 (32) |
| 2017–2019 | 5547 | 1405 (50) | 696 (51) | 482 (53) | 2964 (56) |
| Performance status† | |||||
| 0 | 2659 | 870 (31) | 226 (17) | 213 (23) | 1350 (26) |
| 1 | 3159 | 858 (31) | 338 (25) | 272 (30) | 1691 (32) |
| 2 | 767 | 116 (5) | 211 (16) | 69 (8) | 371 (7) |
| 3+4 | 192 | 16 (1) | 91 (6) | 11 (1) | 74 (1) |
| Unknown | 3529 | 912 (32) | 493 (36) | 342 (38) | 1782 (34) |
| Histology | |||||
| Adenocarcinoma | 5696 | 1129 (41) | 434 (32) | 414 (46) | 3719 (71) |
| Squamous cell | 2742 | 1100 (40) | 572 (42) | 313 (35) | 757 (14) |
| Large cell | 1580 | 506 (19) | 191 (14) | 156 (16) | 727 (14) |
| Other‡ | 288 | 37 (0) | 162 (12) | 24 (3) | 65 (1) |
| EUS | |||||
| Yes | 1294 | 475 (17) | 174 (13) | 137 (15) | 508 (10) |
| No | 9012 | 2297 (83) | 1185 (87) | 770 (85) | 4760 (90) |
| EBUS | |||||
| Yes | 3284 | 1452 (52) | 562 (41) | 355 (39) | 915 (17) |
| No | 7022 | 1320 (48) | 797 (59) | 552 (61) | 4353 (83) |
| Surgical exploration | |||||
| Yes | 87 | 27 (1) | 8 (1) | 13 (1) | 39 (1) |
| No | 10219 | 2745 (99) | 1351 (99) | 894 (99) | 5229 (99) |
| Transthoracic biopsy§ | |||||
| Yes | 808 | 174 (6) | 111 (8) | 81 (9) | 442 (8) |
| No | 4739 | 1231 (44) | 585 (43) | 401 (44) | 2522 (48) |
| Unknown | 4759 | 1367 (50) | 663 (49) | 425 (47) | 2304 (44) |
| Distant metastasis (stage cM)¶ | |||||
| M1a | 1799 | - | - | - | 1799 (34) |
| M1b | 2005 | 2005 (38) | |||
| M1c | 1464 | 1464 (28) | |||
*Percentages were horizontally calculated for each category and the numbers in the column total represent 100%.
†Registered since 2015.
‡Other: Rare histological subtypes, clinical diagnosis.
§Registered since 2017.
¶Located in bone, pleura, lung, adrenal gland, brain, liver, other.
ChemoRT, chemoradiotherapy; EBUS, Endo Bronchial Ultrasound; EUS, endoscopic ultrasound; NSCLC, non-small cell lung cancer; RT, radiotherapy; ST, systemic therapy.